SCHEMBL14378992

SCHEMBL14378992

CCN(c1ccc(C)cc1)c1ccc(OC)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.60
RELA Q04206 1/20 0.48
EGFR P00533 2/20 0.47
PDGFRB P09619 2/20 0.47
KDR P35968 2/20 0.47
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47
TUBB3 Q13509 1/20 0.47
TUBB2A Q13885 1/20 0.47
TUBB8 Q3ZCM7 1/20 0.47
TUBA3E Q6PEY2 1/20 0.47
TUBA1A Q71U36 1/20 0.47
TUBA1C Q9BQE3 1/20 0.47
TUBB6 Q9BUF5 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24247974 0.92 CA1 (0.52) ACHEEGFRPDGFRBKDRTUBB4A
SCHEMBL11474979 0.87 LMNA (0.50) ACHETUBB4ATUBBTUBA3CTUBA1B
SCHEMBL25765524 0.86 ACHE (0.62) ACHERELAEGFRPDGFRBKDR
SCHEMBL516438 0.85 ALDH1A1 (0.50) ACHECNR1CNR2ALDH1A1MAPT
SCHEMBL11747016 0.84 MTNR1A (0.54) EGFRPDGFRBKDRCNR1CNR2
SCHEMBL10065624 0.83 ACHE (0.71) ACHERELACNR1CNR2CA12
SCHEMBL172190 0.83 ACHE (0.71) ACHERELACNR1CNR2CA12
SCHEMBL19958553 0.83 ACHE (0.71) ACHERELACNR1CNR2CA12
SCHEMBL348291 0.83 ACHE (0.71) ACHERELACNR1CNR2CA12
SCHEMBL12545287 0.83 ACHE (0.71) ACHERELACNR1CNR2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BRAF, RAF1, ARAF ACHE 4822/4885RELA 1899/4885EGFR 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.